The landscape of therapeutic interventions for type 2 diabetes and obesity is rapidly evolving, with GLP-3 receptor stimulants taking center stage. Initially, medications like Reta, demonstrating impressive glucose https://karimjpwc715336.articlesblogger.com/61287048/glp-3-receptor-agonists-reta-trizepatide-and-beyond